Inhibikase Therapeutics, Inc. (IKT) Financial Statements
Free cash flow over the same period: -$42.6M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
IKTInhibikase Therapeutics, Inc.Follow IKT — free
—
Price chart with a free account
- Market cap
- 221.9M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 12 Nov, in 19 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Research & development | 11.4 | 12.0 | 13.6 | 17.2 | 29.8 | 38.2 | |
| Operating income | -14.8 | -18.1 | -20.1 | -28.6 | -52.0 | -65.4 | |
| Pre-tax income | -14.8 | -18.1 | -19.0 | -27.5 | -0.0 | — | |
| Income tax | — | — | — | — | 0.0 | 0.0 | |
| Net income | -14.8 | -18.1 | -19.0 | -27.5 | -48.3 | -60.6 | |
| Diluted EPS ($) | -0.81 | -4.28 | -3.16 | -1.16 | -0.49 | -0.35 | |
| Diluted shares (mn) | — | 4.2 | 6.0 | 23.7 | 98.3 | — |
USD millions · SEC XBRL
Inhibikase Therapeutics, Inc. — questions
- What is Inhibikase Therapeutics, Inc.'s net income?
- -$60.6M over the twelve months to 2026-06-30.
- What is Inhibikase Therapeutics, Inc.'s free cash flow?
- -$42.6M over the twelve months to 2026-06-30.
- What are Inhibikase Therapeutics, Inc.'s diluted earnings per share?
- $-0.35 over the twelve months to 2026-06-30.
Every figure on this page comes from Inhibikase Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.